
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems, Inc. has demonstrated significant growth in its operational capacity, increasing its employee count from 1,246 in 2024 to 1,333 by the end of 2025, reflecting the company's expanding workforce dedicated to sales and marketing. The company's advertising expenses also rose substantially, totaling $114.9 million in 2025, a 21% increase from the previous year, indicating a strong commitment to driving market awareness and adoption of its Inspire system for obstructive sleep apnea. Furthermore, projections suggest a robust growth trajectory for the global HGNS market, with anticipated revenue growth rates of +11% and +16% in 2027 and 2028, respectively, supporting a positive long-term outlook for Inspire's financial performance.
Bears say
Inspire Medical Systems has lowered its 2026 revenue guidance from $1,003-$1,013 million to $950-$1,000 million, reflecting slower growth due to reimbursement uncertainties and challenges with the introduction of new coding related to its Inspire system. The financial outlook includes a projected revenue growth rate deceleration and potential headwinds from changes in reimbursement policies, which may disincentivize physicians from performing relevant procedures. Additionally, the rocky execution of its WISeR program and dependency on favorable reimbursement outcomes increase the overall uncertainty regarding Inspire's growth trajectory, warranting a reassessment of its stock valuation.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares